What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc., nothing.
The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.
Study outcome won't sway company on eye drug
A federal appeals court late Friday blocked the ability of doctors to prescribe the abortion pill...
A Pennsylvania court on Monday said that the state’s constitution guarantees a right to abortion while...
A former senior adviser at the National Institute of Allergy and Infectious Diseases is facing charges...
When Bug got home from school one winter afternoon in late 2024, his mother was on...
